Current stock page

Stock Analysis

United Therapeutics Corporation (UTHR) Stock Analysis

United Therapeutics Corporation (UTHR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

UTHR Stock Analysis Summary

United Therapeutics Corporation (UTHR) currently has an AIQ Score of 76/100, indicating a bullish setup. Risk is the strongest factor at 83/100. Momentum is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

UTHR at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$591.17
AIQ Score76/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$25.24B
P/E Ratio (TTM)20.7
Forward P/E—
EPS (Q3 FY2026)$6.06
Revenue (Q3 FY2026)$832.5M
Dividend Yield (TTM)0.00%
Beta0.42
Volume463.51K
52-week range$455.63-$614.23
RSI 1458.01
50-Day SMA$542.60
200-Day SMA$537.46
Analyst Price Target$687.40
Next EarningsFeb 24, 2027
As of Nov 13, 2026 · Market close

UTHRUnited Therapeutics Corporation

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$591.17−$2.14 (−0.36%)

Latest quote

  • Momentum
    68
  • Value
    78
  • Quality
    81
  • Risk resilience
    83
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

UTHR Stock Analysis Summary

United Therapeutics Corporation (UTHR) currently has an AIQ Score of 76/100, indicating a bullish setup. Risk resilience is the strongest factor at 83/100. Momentum is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, UTHR has AIQ Score of 76/100 with Risk resilience base of 83/100 and fading Momentum at 68/100. Wait for component alignment before adding exposure.

Healthcare · -0.36% stock move · UTHR classified in Biotechnology.

Current Evidence

BullishUTHR is in a bullish AIQ regime; Risk resilience is the strongest visible factor at 83/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is UTHR Bullish or Bearish Right Now?

UTHR currently has a bullish overall setup. Risk Resilience is the strongest factor at 83/100, while Momentum is weakest at 68/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 81/100.
  • - Momentum is constructive at 68/100.
  • - Risk Resilience is supportive at 83/100.
  • - Price is +8.95% above its 50-day SMA.
  • - Analyst target implies +16.28% upside from the latest quote.
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

UTHR's Technical Analysis Consensus is currently Strong Buy, with 31 buy, 9 neutral, and 6 sell votes. UTHR's 14-day RSI is 58.01, which places the stock in a constructive momentum range. UTHR's beta is 0.42, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in UTHR?

The largest recent change in UTHR is AIQ Score moving up by 0.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.

AIQ Score
+0.0
Momentum
+0.0
Quality
+0.0
Risk
+0.0

What Would Change the UTHR Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

UTHR Decision Framework

Public evidence layers, setup checks, and risk context for United Therapeutics Corporation.

United Therapeutics Corporation (UTHR) Stock Analysis

United Therapeutics Corporation has an AIQ Score of 76/100 in a Bullish regime. Risk is strongest at 83/100. Beta is 0.42, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextUTHR is in a Bullish AIQ regime with score 76/100.
Signal ConflictThe primary conflict is that risk leads at 83/100 while momentum lags at 68/100.
Factor EvidenceMomentum 68/100 · Value 78/100 · Quality 81/100 · Risk 83/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Risk is the strongest factor at 83/100.

TimingPass

Momentum is 68/100 and RSI (14) is 58.0.

Regime fitPass

UTHR is in a Bullish regime at 76/100.

Risk controlPass

Risk factor is 83/100 with beta 0.42 and annual volatility 35.02%.

ConflictPass

Current conflict: risk leads at 83/100 while momentum lags at 68/100.

AIQ Score
76/100
Price
$591.17
Beta
0.42
RSI (14)
58

UTHR Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

UTHR Fundamentals

UTHR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$832.5M
Net income
$258.6M
Free cash flow
$125.8M
View full UTHR fundamental analysis

UTHR Technical Analysis

UTHR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
58.01
Price vs SMA-50
+8.95%
View full UTHR technical analysis

UTHR Stock Catalysts

Track UTHR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$687.40
News items
4
View UTHR earnings and stock catalysts

UTHR Dividend Analysis

UTHR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View UTHR dividend history and analysis

UTHR Financial Data

UTHR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$832.5M
EPS
$6.06
Periods
8
View UTHR financials

UTHR Risk Analysis

UTHR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.42
Risk score
83/100
1Y volatility
35.02%
View UTHR risk analysis

UTHR Stock News

UTHR stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read UTHR stock news

UTHR vs Biotechnology Peers

Current peer cohort: UTHR · VCEL · VKTX · VOR · VRDN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
UTHR
Current stock
76/10078/10068/10083/1000.7635.02%Current
VCEL
Vericel Corporation
77/10065/10090/10064/1000.9345.04%UTHR vs VCEL
VKTX
Viking Therapeutics, Inc.
41/100—47/10041/100-0.1569.18%UTHR vs VKTX
VOR
Vor Biopharma Inc.
66/100—72/10046/1001.1593.53%UTHR vs VOR
VRDN
Viridian Therapeutics, Inc.
58/10037/10091/10046/1000.4371.98%UTHR vs VRDN
Pairwise Compare links: VCEL · VKTX · VOR · VRDNUTHR vs VCELUTHR vs VKTXUTHR vs VORUTHR vs VRDNCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a UTHR stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for UTHR: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
20.7
As of Nov 13, 2026
Revenue growth
4.13%
Gross margin
86.34%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$832.5M
Quarter net income
$258.6M
Quarter free cash flow
$125.8M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
58.01
MACD
12.7

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
83/100
Beta
0.42
Annual volatility
35.02%
Max drawdown
-20.87%

UTHR Stock FAQ

What is UTHR stock price today?

United Therapeutics Corporation's current stock price is $591.17. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is UTHR bullish or bearish right now?

UTHR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is UTHR's market cap?

UTHR's market cap is $25.24B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is UTHR's current P/E ratio?

UTHR's current P/E ratio is 20.7 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is UTHR's RSI?

UTHR's 14-day RSI is 58.01 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is UTHR above its 50-day and 200-day moving averages?

UTHR is 8.95% from its 50-day SMA and 9.99% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is UTHR's next earnings date?

UTHR's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does UTHR pay a dividend?

UTHR's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.